Aktuellt
SENASTE
Redeye comments on aXichem’s Q2’22 report. We are encouraged to see sales for H1 2022 reaching SEK 1.2m (SEK 0.1m). However, the ramp-up in sales has taken longer than we have expected, and we will shortly return with an update with a case review and financial forecast reconsiderations.
LÄS MER
